Enzolytics and Samsung Biologics link up on anti-HIV and anti-SARS-CoV-2 MAb therapies

South Korean contract development and manufacturing organization (CDMO) Samsung Biologics (KRX: 207940) and US drug developer Enzolytics have signed a strategic CDMO partnership agreement.

Under the terms of the agreement, financial details of which are not disclosed, Samsung Biologics, whose shares moved up 3% on the news, will provide end-to-end CDMO services from cell line development, clinical drug substance, and drug product manufacturing services to support investigational new drug (IND) filings for anti-HIV and anti-SARS-CoV-2 monoclonal antibodies (MAbs) for the treatment of HIV and SARS-CoV-2. In addition, there will be continuing discussions for other MAbs being developed by Enzolytics.

The Enzolytics protocol offers the opportunity to implement AI analysis and provides a platform for creating multiple fully human MAbs targeting conserved immutable sites on the virus and offering a cure for these viruses. A stable cell line will be manufactured with support from Samsung Biologics' R&D Center in San Francisco. Its related clinical trial materials will be manufactured at Samsung Biologics headquarters in Incheon, South Korea.